Loading organizations...
Key people at Broad Institute of MIT and Harvard.
The Broad Institute of MIT and Harvard is a nonprofit biomedical and genomic research center based in Cambridge, Massachusetts, that investigates the molecular basis of diseases to develop new diagnostics and therapeutics. Operating as a 501(c)(3) organization, the institute engages a network of more than 6,000 researchers, including 24 core faculty and 195 associate members across its partner institutions. The research center collaborates extensively with academic and corporate entities, maintaining strategic partnerships with organizations such as Massachusetts General Hospital, Dana-Farber Cancer Institute, Bayer, and Novo Nordisk. Its scientific output spans oncology, cardiovascular health, and infectious diseases, recently contributing to the FDA accelerated approval of a novel lung cancer drug and developing scalable cell painting methods for drug safety testing. The organization was founded in 2004 by philanthropists Eli and Edythe Broad alongside MIT and Harvard University.
The Broad Institute of MIT and Harvard is a nonprofit biomedical research institute that develops and shares genomic, chemical and computational tools to understand disease biology and accelerate new therapies, operating as a collaborative hub that brings together scientists from MIT, Harvard, affiliated hospitals and partner institutions[1][8].
High-Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech/Biomed Landscape
Quick Take & Future Outlook
Key people at Broad Institute of MIT and Harvard.